title: Critical role of cytosolic phospholipase A2{alpha} in bronchial mucus hypersecretion in CFTR-deficient mice.
abstract: Cystic fibrosis (CF) is due to mutations in the CF transmembrane conductance regulator gene CFTR. CF is characterised by mucus dehydration, chronic bacterial infection and inflammation, and increased levels of cytosolic phospholipase A2α (cPLA2α) products in airways. We aimed to examine the role of cPLA2α in the modulation of mucus production and inflammation in CFTR-deficient mice and epithelial cells. Mucus production was assessed using histological analyses, immuno-histochemistry and MUC5AC ELISA. cPLA2α activation was measured using an enzymatic assay and lung inflammation determined by histological analyses and polymorphonuclear neutrophil counts in bronchoalveolar lavages. In lungs from Cftr(-/-) mice, lipopolysaccharide induced mucus overproduction and MUC5AC expression associated with an increased cPLA2α activity. Mucus overproduction was mimicked by instillation of the cPLA2α product arachidonic acid, and abolished by either a cPLA2α null mutation or pharmacological inhibition. An increased cPLA2α activity was observed in bronchial explants from CF patients. CFTR silencing induced cPLA2α activation and MUC5AC expression in bronchial human epithelial cells. This expression was enhanced by arachidonic acid and reduced by cPLA2α inhibition. However, inhibition of CFTR chloride transport function had no effect on MUC5AC expression. Reduction of CFTR expression increased cPLA2α activity. This led to an enhanced mucus production in airway epithelia independent of CFTR chloride transport function. cPLA2α represents a suitable new target for therapeutic intervention in CF.
authors.affiliation: Unité de Défense Innée et Inflammation, Inserm, Paris, France.
authors.forename: F
authors.initials: F
authors.lastname: Dif
authors.forename: Y-Z
authors.initials: YZ
authors.lastname: Wu
authors.forename: P-R
authors.initials: PR
authors.lastname: Burgel
authors.forename: M
authors.initials: M
authors.lastname: Ollero
authors.forename: D
authors.initials: D
authors.lastname: Leduc
authors.forename: J
authors.initials: J
authors.lastname: Aarbiou
authors.forename: F
authors.initials: F
authors.lastname: Borot
authors.forename: I
authors.initials: I
authors.lastname: Garcia-Verdugo
authors.forename: C
authors.initials: C
authors.lastname: Martin
authors.forename: M
authors.initials: M
authors.lastname: Chignard
authors.forename: D
authors.initials: D
authors.lastname: Israel-Biet
authors.forename: Y
authors.initials: Y
authors.lastname: Kita
authors.forename: B J
authors.initials: BJ
authors.lastname: Scholte
authors.forename: L
authors.initials: L
authors.lastname: Touqui
mesh_terms: D000818:Animals; D016718:Arachidonic Acid / Q000378:metabolism; D001980:Bronchi / Q000166:cytology / Q000378:metabolism*; D002460:Cell Line; D002712:Chlorides / Q000378:metabolism; D019005:Cystic Fibrosis Transmembrane Conductance Regulator / Q000235:genetics* / Q000378:metabolism; D003600:Cytosol / Q000378:metabolism; D004195:Disease Models, Animal; D054513:Group IV Phospholipases A2 / Q000235:genetics* / Q000378:metabolism*; D006801:Humans; D008070:Lipopolysaccharides / Q000494:pharmacology; D051379:Mice; D008810:Mice, Inbred C57BL; D018181:Mice, Inbred CFTR; D055271:Mucin 5AC / Q000235:genetics / Q000378:metabolism*; D009093:Mucus / Q000378:metabolism*; D034741:RNA, Small Interfering; D020545:Respiratory Mucosa / Q000166:cytology / Q000378:metabolism
chemical_list: D002712:Chlorides; D008070:Lipopolysaccharides; C524678:MUC5AC protein, human; C524679:Muc5ac protein, mouse; D055271:Mucin 5AC; D034741:RNA, Small Interfering; D019005:Cystic Fibrosis Transmembrane Conductance Regulator; D016718:Arachidonic Acid; D054513:Group IV Phospholipases A2